The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies.
 
Arthur Geraud
Employment - Drug Impairment Training for Educational Professionals (DITEP)
Consulting or Advisory Role - Hengrui Therapeutics
Research Funding - Drug Impairment Training for Educational Professionals (DITEP)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
David Combarel
No Relationships to Disclose
 
Christian Funck-Brentano
No Relationships to Disclose
 
Quentin Beaulien
No Relationships to Disclose
 
Noel Zahr
No Relationships to Disclose
 
Sophie Broutin
No Relationships to Disclose
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; BMS; Celgene; Debiopharm Group; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Genentech/Roche; INNATE PHARMA; IPSEN; Janssen; Lilly; MSD; Novartis; ORION; Pfizer; PharmaMar; Sanofi; Taiho Pharmaceutical
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Genzyme (Inst); Genzyme (Inst); Hedera Dx (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); socar (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst)
 
Paul Gougis
No Relationships to Disclose